{"disease":{"id":"second-line-treatment-for-locally-advanced-or-metastatic-pancreatic-cancer-after-treatment-failure-with-gemcitabine-based-therapy","name":"second line treatment for locally advanced or metastatic pancreatic cancer after treatment failure with gemcitabine based therapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05074589","title":"Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}